# Etanercept (Enbrel®) in Psoriasis - Pediatrics

> **NCT00078819** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 211 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00078819
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09-08
- **Primary completion:** 2006-02-01
- **Final completion:** 2007-06-01
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2019-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00078819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00078819, "Etanercept (Enbrel®) in Psoriasis - Pediatrics". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00078819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*